Actively Recruiting
Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT
Led by Second Affiliated Hospital of Guangzhou Medical University · Updated on 2024-07-01
90
Participants Needed
1
Research Sites
602 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This trial is designed to investigate the safety, response rates and survival outcomes of patients with hepatocellular carcinoma by infusion of CTLA4, PD1 and PDL1 antibodies combination with chemodrug or/and bevacizumab through intra-tumor (IT).
CONDITIONS
Official Title
Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Confirmed cancer diagnosis by tissue testing (cytohistological confirmation)
- Signed informed consent before joining the study
- Age 18 years or older with expected survival longer than 3 months
- Child-Pugh class A or B with Child score greater than 7 and ECOG score less than 2
- Acceptable or reversible blood clotting function
- Recent laboratory results within 7 days meeting specified blood counts and liver function levels
- At least one measurable tumor lesion per RECIST v1.1 criteria
- Using birth control methods
- Willing and able to follow the treatment schedule and attend visits and tests
You will not qualify if you...
- Participation in any clinical trial with drugs or equipment in the last 4 weeks
- Presence of ascites, hepatic encephalopathy, or bleeding from esophageal or gastric varices
- Serious diseases affecting prognosis such as heart disease, uncontrolled diabetes, or psychiatric disorders
- Presence of other tumors or history of other cancers
- Pregnant or breastfeeding
- Poor compliance with treatment or study requirements
- Contraindications for hepatic arterial infusion including low platelet count, low prothrombin activity, renal failure requiring dialysis, severe atherosclerosis, or uncontrolled high blood pressure
- Allergy to contrast agents
- Use of medications affecting drug absorption or pharmacokinetics
- Any other conditions the investigator considers unsuitable for the trial
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, China, 510260
Actively Recruiting
Research Team
Z
Zhenfeng Zhang, MD, PhD
CONTACT
B
Bingjia He, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here